Main Content

Attention Deficit Hyperactivity Disorder (ADHD)


If you find any errors or omissions in these Guidelines, or feel that something in them needs to change, write to:

Please include details of the page on which you wish to provide feedback.

Thank you for your assistance in ensuring that these Guidelines are up to date and correct.

Search again

Aeromedical Implications

Effect of condition on aviation

  • Premature and ill-considered actions
  • Restlessness and excess of movement causing distraction
  • Impaired split attention affecting multi-tasking and situational awareness

Approach to medical certification

Based on the condition

  • In full remission

Based on Treatment

  • No safety-relevant medication such as stimulants

Demonstrated Stability

  • Absence of symptoms for a minimum of 6 months after treatment completed. (Reflects DSMIV diagnostic criteria)

Risk assessment protocol - Information required

New cases

  • Copies of medical records from date of diagnosis to the present
  • Copies of records from Medicare detailing consultations and prescription of medications
  • An up to date assessment by the treating paediatrician or psychiatrist if available detailing:
    • History of condition
    • Precise confirmation of the diagnosis with reference to DSM-IV criteria
    • Co-morbidities, including drug and alcohol use
    • Requirement and response to treatment
    • Current clinical status with respect to DSM-IV criteria
    • Current functional status, with reference to collateral information if available from school, family, workplace etc.
  • Completion by the paediatrician/psychiatrist and the chief flying instructor of Form 420 Instructor's Questionnaire regarding symptoms in the context of and noting the implications to both the normal day to day life and the conduct of aviation. Attached questionnaire
  • Copies of academic records and employment history
  • Copies of traffic infringements and criminal records
  • Copies of any special investigations performed such as QEEG or neuropsychological testing
  • Follow-up plan
  • Previous specialist reports if available


  • May be subject to annual review by an appropriate specialist on a case by case basis.

Indicative outcomes


  • Stable off medication for at least 6 months and satisfactory reports
  • Instructor questionnaire and annual specialist reports for 5 years following cessation of treatment. After 5 years consideration of removal of surveillance requirement.


  • Recurrence of symptoms
  • Stimulant medication

Pilot & Controller Information

  • Any recurrence must be reported to the DAME


The Clinical Practice Guideline is provided by way of guidance only and subject to the Clinical practice guidelines disclaimer